Biolegend, 628501, Purified anti-Cytokeratin 19 Antibody, 25μg

Cytokeratin 19, also known as keratin 19, is a type I intermediate filament protein with a molecular weight of approximately 40-44 kD. Cytokeratin 19 is a heterotetramer composed of two type I and two type II keratin subunits. Unlike other cytokeratins, cytokeratin 19 lacks a C-terminal non-helical extension. This cytokeratin is widely expressed in the periderm (transient superficial layer enveloping developing epidermis), muscle, intestine, bile duct, esophagus, stomach, and thymus. Cytokeratin 19 can be upregulated by vitamin A and is thought to play a critical role in embryogenesis. Cytokeratin 19 intereacts with the pinin protein and has been shown to be modified by phosphorylation (Ser10, Ser35).
25μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human mammary carcinoma cell line MCF-7
Formulation: This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide at 0.5 mg/ml.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: WB - Quality testedICC - VerifiedIP, IHC-P, ELISA - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 5 µg antibody per 5 ml antibody dilution buffer for each mini-gel. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation, immunohistochemistry of paraffin-embedded sections, immunocytochemistry, and ELISA.
Application References(PubMed link indicates BioLegend citation): Karsten U, et al. 1985. Eur. J. Cancer Clin. Oncol. 21:733. Nishikata T,et al. Anticancer Res. 33:2867. PubMed
Product Citations: Haensel D, et al. 2022. Nat Commun. 13:7520. PubMed McMahon NP, et al. 2023. Cancers (Basel). 15: . PubMed Burlingame EA, et al. 2021. Cell Rep Methods. 1:. PubMed Risom T, et al. 2020. J Clin Invest. 130:231. PubMed Shalabi SF, et al. 2021. Nat Aging. 1:838. PubMed NISHIKATA T, et al. 2013. Anticancer Res. 33:2867. PubMed Rohena C, et al. 2013. Biochem Pharmacol. 85:1104. PubMed Li Z, et al. 2020. J Clin Lab Anal. 34:e23155. PubMed Johnson BE, et al. 2022. Cell Rep Med. 3:100525. PubMed
RRID: AB_439773 (BioLegend Cat. No. 628502)
Structure: Type I intermediate filament protein, contains three coiled-coil domains, lacks C-terminal non-helical extension found in other keratins, approximately 40-44 kD. Cytokeratin 19 is a heterotetramer composed of two type I and two type II keratin subunits.
Distribution: Expressed in the periderm (transient superficial layer enveloping developing epidermis), also expressed in muscle, intestine, bile duct, esophagus, stomach, and thymus. Upregulated by vitamin A.
Function: Intermediate filament protein involved with the cytoskeleton. May play a critical role in embryogenesis
Interaction: Interacts with pinin
Modification: Phosphorylation (Ser10, Ser35)
Biology Area: Cell Biology, Cell Motility/Cytoskeleton/Structure, Neuroscience, Neuroscience Cell Markers
Molecular Family: Intermediate Filaments
Antigen References: 1. Bader BL, et al. 1986. EMBO J. 5:1865. 2. Eckert RL. 1988. Proc. Natl. Acad. Sci. 85:1114. 3. Stasiak PC and Lane EB. 1987 Nucleic Acids Res. 15:10058.
Gene ID: 3880
UniProt: View information about Cytokeratin 19 on UniProt.org
Clone: A53-B/A2
Regulatory Status: RUO
Other Names: Keratin 19, Keratin 19 type 1 cytoskeletal
Isotype: Mouse IgG2a, κ